WO2020055934A1 - Systèmes et procédés de désactivation de champs opératoires adhésifs sensibles à la lumière - Google Patents

Systèmes et procédés de désactivation de champs opératoires adhésifs sensibles à la lumière Download PDF

Info

Publication number
WO2020055934A1
WO2020055934A1 PCT/US2019/050497 US2019050497W WO2020055934A1 WO 2020055934 A1 WO2020055934 A1 WO 2020055934A1 US 2019050497 W US2019050497 W US 2019050497W WO 2020055934 A1 WO2020055934 A1 WO 2020055934A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesive portions
photosensitive adhesive
drape
tissue
layer
Prior art date
Application number
PCT/US2019/050497
Other languages
English (en)
Inventor
Timothy Mark Robinson
Christopher Locke
Ashwatha PRICE
Original Assignee
Kci Licensing, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kci Licensing, Inc. filed Critical Kci Licensing, Inc.
Publication of WO2020055934A1 publication Critical patent/WO2020055934A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0246—Adhesive plasters or dressings characterised by the skin adhering layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0246—Adhesive plasters or dressings characterised by the skin adhering layer
    • A61F13/025—Adhesive plasters or dressings characterised by the skin adhering layer having a special distribution arrangement of the adhesive

Definitions

  • the present application relates generally to the field of tissue treatment, and more specifically to a system and method for facilitating the application and removal of a drape from a tissue site.
  • tissue treatment systems require the use of an adhesive drape to secure all or a portion of the tissue treatment system to a tissue site.
  • an adhesive drape can be used to secure a gauze portion of a bandage to a wound site by adhering to the skin or other tissue surrounding the wound.
  • Drapes intended for use with negative pressure wound therapy (NPWT) have certain desirable characteristics.
  • the drape is easy to apply, doesn't adhere well to itself if folded (e.g., adhesive to adhesive) upon application to tissue, achieves a good seal with the tissue, adheres well to tissue and to its film (e.g., polyurethane) covering when layered or overlapped, enables atraumatic removal, is highly breathable, is repositionable upon application, and achieves adhesion that is not affected by patient heat or sweat.
  • AWD advanced wound dressing
  • a challenge with bordered AWDs is to get a balance of adhesive strength vs. trauma upon removal at the optimum point for a wide range of users and skin types.
  • AWDs are used on a wide range of chronic wounds and thus on a wide range of patients, some of whom have delicate and friable skin and others who have a high degree of sensitivity to pain. If the adhesive is insufficiently strong, the adhesive can give way during wear and result in fluid leaks which can be distressing for the patient, or the dressing can come away from the patient. If the adhesive is too aggressive, it can be painful upon removal and result in skin stripping.
  • Silicones and other adhesives have been used to try to reduce trauma; however, these can lack bond strength and can be adversely affected by moisture. Therefore, a strong adhesive drape is needed which maintains adhesion during the length of the wound therapy but does not result in any trauma to the tissue when the dressing is removed.
  • Some drape systems include an adhesive that, when exposed to UV light, will crosslink and reduce its bond strength with skin. This configuration enables a user to be able to release or remove the drape with low or no trauma to the surrounding tissue. Since the occurrence of UV light in indoor lighting is very low if not non-existent, the carrier film of the drape may be clear because the risk of premature deactivation of the adhesive is low while indoors. In this instance, a separate source of UV light (e.g., torch or flashlight) is required and is used to dose and subsequently crosslink the adhesive to permit removal. However, if the UV torch fails to work or is lost, the user is faced with a highly bonded drape that is likely to cause high trauma when it is removed. Unless the drape is exposed to some other UV light source (e.g., daylight), there is little that can be done to reduce the switchable adhesive’s bond strength in a relatively short time.
  • some other UV light source e.g., daylight
  • a removable light blocking film layer be opaque in one or more areas to block deactivating wavelengths from prematurely reaching the light switchable adhesive.
  • the opaque removable light blocking film layer is selectively applied to only certain parts of the dressing.
  • a light deactivated adhesive drape system configured to be coupled to tissue, the system comprising: a drape comprising: a breathable film; a plurality of first photosensitive adhesive portions disposed on the breathable film and configured to adhere to the tissue and having at least one first release agent disposed within the adhesive portions, wherein the at least one first release agent is configured to weaken a bond of the plurality of first photosensitive adhesive portions to the tissue upon exposure to at least one of a plurality of ultraviolet light wavelengths; and a plurality of second photosensitive adhesive portions separate from the plurality of first photosensitive adhesive portions, the plurality of second photosensitive adhesive portions being disposed on the breathable film and configured to adhere to the tissue and having at least one second release agent different than the at least one first release agent disposed within the adhesive portions, wherein the at least one second release agent is configured to weaken a bond of the plurality of second photosensitive adhesive portions to
  • the plurality of first photosensitive adhesive portions and the plurality of second photosensitive adhesive portions are pattern coated onto the breathable film.
  • the plurality of first photosensitive adhesive portions comprise a plurality of dots.
  • the plurality of second photosensitive adhesive portions comprise a plurality of dots.
  • the plurality of first photosensitive adhesive portions comprise an adhesive layer pattern coated onto the breathable film and the plurality of second photosensitive adhesive portions comprise a plurality of dots pattern coated onto the adhesive layer.
  • the plurality of second photosensitive adhesive portions comprise an adhesive layer pattern coated onto the breathable film and the plurality of first photosensitive adhesive portions comprise a plurality of dots pattern coated onto the adhesive layer.
  • the breathable film comprises at least one of acrylic or polyurethane.
  • the drape further comprises a removable blocking layer configured to block the plurality of visible light wavelengths that activate the at least one second release agent, wherein the plurality of visible light wavelengths are wavelengths comprising a portion of the visible light spectrum.
  • the plurality of second photosensitive adhesive portions are deactivated by removing the removable blocking layer from the drape to expose the plurality of second photosensitive adhesive portions to the plurality of visible light wavelengths.
  • the plurality of first photosensitive adhesive portions comprise a first adhesive layer coated onto a second adhesive layer comprising the plurality of second photosensitive adhesive portions.
  • the first adhesive layer comprises a plurality of perforations.
  • the at least one second release agent is additionally configured to weaken a bond of the plurality of second photosensitive adhesive portions to the tissue upon exposure to the at least one of a plurality of ultraviolet light wavelengths.
  • the first film layer is pattern coated onto the second film layer. In some embodiments, the first film layer is a continuous coating. In some embodiments, the first film layer comprises a plurality of perforations. In some embodiments, the breathable film comprises at least one of acrylic or polyurethane.
  • the drape further comprises a removable blocking layer configured to block the plurality of visible light wavelengths that activate the at least one second release agent, wherein the plurality of visible light wavelengths are wavelengths comprising a portion of the visible light spectrum.
  • the plurality of second photosensitive adhesive portions are deactivated by removing the removable blocking layer from the drape to expose the plurality of second photosensitive adhesive portions to the plurality of visible light wavelengths.
  • the removable blocking layer includes at least one non-opaque portion that comprises a viewing area configured to enable viewing of the tissue beneath the drape.
  • a method comprising: coupling the drape system of any of the disclosed embodiments to a patient’s tissue; exposing the plurality of first photosensitive adhesive portions and the plurality of second photosensitive adhesive portions to the at least one of the plurality of visible light wavelengths configured to weaken the bond of the plurality of second photosensitive adhesive portions; and removing the drape from the tissue.
  • the terms“a” and“an” are defined as one or more unless this disclosure explicitly requires otherwise.
  • the term“substantially” is defined as largely but not necessarily wholly what is specified (and includes what is specified; e.g., substantially 90 degrees includes 90 degrees and substantially parallel includes parallel), as understood by a person of ordinary skill in the art.
  • the terms“substantially,”“approximately,” and “about” may be substituted with“within [a percentage] of’ what is specified, where the percentage includes 0.1, 1, 5, and 10 percent.
  • a method that“comprises,”“has,” “includes” or“contains” one or more steps possesses those one or more steps, but is not limited to possessing only those one or more steps.
  • terms such as“first” and “second” are used only to differentiate structures or features, and not to limit the different structures or features to a particular order.
  • any embodiment of any of the disclosed methods, systems, system components, or method steps can consist of or consist essentially of— rather than comprise/include/contain/have— any of the described elements, steps, and/or features.
  • the term“consisting of’ or“consisting essentially of’ can be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
  • FIGS. 1A-1B are cross-sectional views of a light deactivated adhesive drape system in accordance with an illustrative embodiment of the present disclosure.
  • FIGS. 2A-2C are cross-sectional views of a light deactivated adhesive drape system in accordance with another illustrative embodiment of the present disclosure.
  • FIG. 3 is a top-down view of a light deactivated adhesive drape system in accordance with another illustrative embodiment of the present disclosure.
  • FIG. 4 is a perspective view of a light deactivated adhesive drape system in accordance with another illustrative embodiment of the present disclosure.
  • FIG. 5 is a top-down view of a light deactivated adhesive drape system in accordance with another illustrative embodiment of the present disclosure.
  • FIG. 6 is a flowchart illustrating a process for using a light deactivated adhesive drape system in accordance with an illustrative embodiment of the present disclosure.
  • FIG. 7 is a flowchart illustrating a process for using a light deactivated adhesive drape system in accordance with another illustrative embodiment of the present disclosure.
  • Reduced pressure generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure of the location at which the patient is located.
  • vacuum and “negative pressure” can be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site can be significantly less than the pressure normally associated with a complete vacuum. Consistent with this nomenclature, an increase in reduced pressure or vacuum pressure refers to a relative reduction of absolute pressure, while a decrease in reduced pressure or vacuum pressure refers to a relative increase of absolute pressure.
  • the term “coupled” includes “indirect coupling” via a separate object.
  • a drape can be coupled to the tissue site if both the drape and the tissue site are coupled to one or more third objects, such as a release agent or a second adhesive layer.
  • the term “coupled” also includes “directly coupled,” in which case the two objects touch each other in some way.
  • the term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material.
  • the term “coupled” includes chemical coupling, such as via a chemical bond, and electrostatic coupling.
  • Various aspects of the present invention comprise a system and method for systems and methods for mitigating premature light deactivation of light deactivated adhesive drapes, a portion of which is shown in each of the FIGS. 1A-7.
  • Various embodiments can facilitate the removal of the drape from the tissue site with less trauma to a patient than conventional drapes while preventing premature deactivation of the adhesive.
  • the tissue site may be skin tissue, wound tissue, bone tissue, or any other type of tissue.
  • Various embodiments of the system and method described herein comprise, or can be used with reduced or negative pressure wound healing technology.
  • FIGS. 1A and 1B an illustrative embodiment of a light deactivated adhesive drape system 100 disposed onto patient tissue 104 is shown, also referred to a tissue 104 herein.
  • the light deactivated adhesive drape system 100 (also referred to herein as system 100 or drape system 100) comprises an absorbent drape portion 108 (referred to as“absorbent portion 108” herein), a drape cover 112, an adhesive layer 116 having at least one photosensitive adhesive portion 120 and at least one acrylic and/or polyurethane adhesive portion 124.
  • both adhesive portions 120 and 124 are coupled to the drape cover 112.
  • a drape can be generally understood to be a covering over a tissue 104 that is preferably sterilizable.
  • a drape can comprise a biocompatible thin film material, such as a polymer, a woven or non- woven material, an elastic or non-elastic material, an occlusive or nonocclusive material, and a flexible or inflexible material.
  • a drape can comprise an impermeable, semi-permeable, or permeable material. Permeability characteristics can be selected according to desired moisture and gas (e.g., oxygen) transmission.
  • the drape comprises a material relatively impermeable to moisture and relatively permeable to oxygen.
  • a drape can be coated with a material, for example, to control breathability.
  • a drape can comprise a material which allows or facilitates transmission of external stimuli, such as light, sound, moisture or heat.
  • a drape material can be semi- or substantially transparent to electromagnetic radiation, such as visible, ultraviolet (UV), or infrared light.
  • a drape can be composed of one or more layers.
  • a drape can be a bilayer drape.
  • three, four, or more drape layers may be used, with combinations of materials selected according to desired function.
  • the absorbent portion 108 is a tissue contacting material that is therapeutic and promotes healing of a wound.
  • the absorbent portion 108 can be a hydrophilic foam, foam and absorbent laminate, alginate, hydro -polymer, textile, and/or non-woven or bio-polymer such as a collagen. This list of absorbent materials is non- exhaustive and any suitable absorbent, protective, and therapeutic material can be used. In the embodiments shown, the absorbent portion 108 can form a central island in the drape system 100 about which the adhesive layer 116 is used to fixate the absorbent material to the patient for the benefit of the wound and management of fluids.
  • drape cover 112 is placed over absorbent portion 108.
  • adhesive layer 116 comprising photosensitive adhesive portions 120 and acrylic and/or polyurethane adhesive portions 124 on its underside (skin/island facing side).
  • acrylic and/or polyurethane adhesive portions 124 can be used to hold the drape system 100 together.
  • adhesive layer 116 extends around the border of the island of absorbent portion 108 (e.g., such as absorbent material thereof) and is used to affix the AWD to a patient.
  • adhesive layer 116 can be pattern printed to provide areas of adhesive and areas without adhesive where greater MVTR can allow for improved evaporation from the absorbent portion 108 (e.g., such as absorbent material thereof). Both the drape cover 112 and adhesive layer 116 should not impede the transmission of the appropriate wavelengths and intensities of light required to activate and cause the switching of the photosensitive adhesive portions 120.
  • the drape cover 112 and adhesive layer 116 are optically transparent, which may enhance weakening of the adhesive layer by not impeding or reducing the impediment to the transmission of the appropriate wavelengths and intensities of light.
  • the drape cover 112 and/or adhesive layer 116 may be tinted with a color. In these embodiments, the tint color should not disrupt the passage of the appropriate wavelengths and intensities of light required to activate and cause the switching of the photosensitive adhesive portions 120.
  • the drape cover 112 may be a breathable and/or semiporous film such as polyurethane or a thin foam but other suitable materials may be used. There are a range of materials which the drape cover 112 can be formulated from although they generally need to be thin, flexible and have a moderate to high MVTR.
  • the adhesive layer 116 adheres to the tissue 104 thereby coupling the drape cover 112 to the tissue 104.
  • the drape cover 112 may cover any portion of the absorbent portion 108, the adhesive layer 116, and the tissue 104 as may be required.
  • the adhesive portions 124 can comprise one or more materials including, but not limited to, polyurethane, acrylic (e.g., cyanoacrylate), hydrogel, silicon or silicone based material, natural rubber, synthetic rubber, styrene block copolymers, polyvinyl ethers, poly(meth)acrylates, polyolefins, hydrocolloid (e.g., a rubber based hydrocolloid), or a combination thereof.
  • the adhesive portions 124 comprises a polymer or co-polymer.
  • the adhesive portions 124 can comprise a co-polymer of polyurethane and silicone or various acrylic co-polymers.
  • the photosensitive adhesive portions 120 may include at least one release agent 128 comprising a release material.
  • photosensitive adhesive portions 120 have a plurality of release agents 128 (represented by dots).
  • the release agent 128 can physically or chemically affect adhesion characteristics between a drape and a tissue 104.
  • a release agent 128 can comprise a variety of molecular compositions depending on the particular embodiment being implemented, including but not limited to a photopolymer, an oil particle, a gas particle, a solvent, a lipid, and/or one or more microstructures. Release agents 128 can be present in an inert or inactive form in, on, or near adhesive portions 120.
  • a release agent 128 can be mixed with the adhesive; on the surface of the adhesive with a random or patterned coverage; coupled to the drape with a random or patterned coverage; or contained within a microstructure located in these or other locations.
  • release agents 128 can migrate within the adhesive portions 120 or along an interface between adhesive portions 120 and a tissue 104 to facilitate the removal of a drape affixed thereto.
  • the release agent 128 is configured to transition from an unreleased state (shown in FIG. 1A) to a release state 132 (represented by diagonal lines in FIG. 1B) to weaken a bond of adhesive portions 120 to the tissue 104 upon exposure to an external stimulus.
  • an unreleased state shown in FIG. 1A
  • a release state 132 represented by diagonal lines in FIG. 1B
  • Non-limiting examples of the external stimulus include electromagnetic (e.g., UV, visible, or infrared light), magnetic, sound, pH, pressure (e.g., positive atmospheric pressure, negative atmospheric pressure, shear force, direct force), thermal, moisture, or a substance.
  • the external stimulus can also be a substance, compound, liquid, or gas capable of reacting with a release agent 128 in adhesive portions 120 such that the release agent 128 transitions from an unreleased state to a released state.
  • the external stimulus is one or more of a plurality of light wavelengths.
  • the weakened bond that occurs as a result of the release of release agent 128 allows a user of the light deactivated adhesive drape system 100 to apply an upward force on drape cover 112, such as a force indicated by arrow 136, to remove drape cover 112 from tissue 104.
  • the weakened bond reduces the stress applied to tissue 104 in the removal of drape cover 112 from tissue 104.
  • a residue of molecules from adhesive layer 116 might remain on tissue 104 after removal of drape cover 112 depending on a variety of factors such as the type of release agent used.
  • release agents 128 are inertly dispersed within adhesive portions 120 and can be located anywhere within adhesive portions 120, as well as any of the outer surfaces of adhesive portions 120, such as an interface between adhesive portions 120 and drape cover 112.
  • release agents 128 can be bonded or coupled directly to drape cover 112, and a separate film layer (not shown in FIG. 1A), can separate release agents 128 from adhesive portions 120.
  • the presence of an external stimulus can weaken, break-down, or increase the permeability of the separate film layer such that release agents 128 are allowed to migrate into adhesive portions 120 to facilitate the removal of drape cover 112 from tissue 104. As shown in FIG.
  • release agents 128 may be released in the presence of external stimulus such that release agents 128 are allowed to migrate within adhesive portions 120 and the interface between adhesive portions 120 and tissue 104.
  • a light source 140 exposes drape cover 112 and adhesive layer 116 to a plurality of light wavelengths 144.
  • the light source 140 can be a UV light source or a light source that emits visible light wavelengths.
  • exposure to the plurality of light wavelengths 144 can cause microstructures containing release agents 128 to rupture or tear, thereby releasing release agents 128 from the interior of the microstructures.
  • release agents 128 can then be interspersed into adhesive portions 120 and the interface between adhesive portions 120 and tissue 104, thereby weakening the bond between drape cover 112 and tissue 104 and facilitating the removal of drape cover 112 from tissue 104.
  • release agents 128 may transition from an unreleased state (as shown in FIG. 1A) to a released state 132 (as shown in FIG. 1B) as they are exposed to the plurality of light wavelengths 144.
  • the UV wavelengths may be within a range of 280 nm - 395 nm, although it may be preferable to have the UV wavelengths be UVA wavelengths within a range of 315 nm - 395 nm.
  • the visible light wavelengths may be within a range of 400 nm - 700 nm, although it may be preferable to have the visible light wavelengths be wavelengths within a range of 400 nm - 500 nm.
  • the photosensitive adhesive portions 120 can be optimized to deactivate in ⁇ 5 minutes of exposure to a range of ambient light levels, wavelengths, and intensities ranging from environments such as a domestic location with artificial light bulbs (e.g., hospital wards) and strong outdoor light.
  • the intensity of the light source may affect the time it takes for the switchable adhesive to deactivate (i.e., the deactivation time may be less when the intensity of the light is higher such as when exposed to outdoor sunlight vs. indoor ambient light). Switchable adhesives with other deactivation times may be used, such as times within a range of 30 seconds to 6 minutes.
  • light deactivated adhesive drape system 200 is configured to release adhesive portions 120 upon exposure to ambient, visible light instead of UV light.
  • adhesive portions 120 may be constructed with release agents 128 that only release upon exposure to certain wavelengths of visible light.
  • release agents 128 will only transition to a released state 132 when exposed to visible light wavelengths in the blue and violet portions of the visible light spectrum.
  • a blocking layer 204 is disposed over drape cover 112 of the drape.
  • blocking layer 204 is configured to block the visible light wavelengths that release the adhesive portions 120 while allowing other visible light wavelengths to pass through.
  • blocking layer 204 when exposed to visible light, blocking layer 204 will block the blue and violet wavelengths but allow the red, orange, yellow, and/or green wavelengths to pass through. In this way, blocking layer 204 can be partially transparent and enables a clinician or a nurse to visually inspect the drape and the wound site without premature deactivation of the adhesive portions 120.
  • blocking layer 204 can be opaque and/or partially or fully light occlusive.
  • blocking layer 204 is a colored layer that contains a dye or other coloring agent corresponding to one or more colors of the visible light spectrum that have wavelengths that do not deactivate the adhesive portions 120 (e.g., red, orange, yellow, and/or green).
  • blocking layer 204 is a photo-reactive polymer or can incorporate a photo-reactive dye such that blocking layer 204 is transparent when exposed to light of a wavelength/intensity insufficient to deactivate the switchable adhesive but becomes fully light occlusive when exposed to light of a wavelength/intensity sufficient to trigger the deactivation the switchable adhesive.
  • blocking layer 204 is configured to be removable. This enables the adhesive portions 120 to be deactivated at a time a user desires to remove the drape from tissue 104.
  • the blocking layer 204 can be a printed layer printed directly onto the drape cover 112 or the adhesive portions 120.
  • blocking layer 204 can be a peelable layer that adheres to the outer surface of drape cover 112. In the embodiment shown, blocking layer 204 can cover the entire surface of drape cover 112. In other embodiments, blocking layer 204 can cover only the surfaces of drape cover 112 over adhesive portions 120.
  • a user of the light deactivated adhesive drape system 200 can apply a force on blocking layer 204, such as a force indicated by arrows 208, to remove blocking layer 204 from drape cover 112.
  • the adhesive portions 120 can be exposed to deactivation wavelengths (e.g., ambient light 212) that comprises light wavelengths configured to deactivate adhesive portions 120.
  • deactivation wavelengths e.g., ambient light 212
  • release agents 128 can transition from an unreleased state to a released state 132.
  • the drape including drape cover 112 can then be removed from tissue 104. If any residue of adhesive portions 120 remains on tissue 104 after removal of the drape, it may be removed.
  • blocking layer 204 is a frequency/intensity/UV blocking film layer which may be transparent or fully occlusive. Transparency will depend on the ability of the selected material to completely and totally block any activating wavelengths from the switchable adhesive under all light and environmental conditions. This material should optimally be highly breathable with a high MVTR. It can also incorporate an adhesive that may be acrylic, polyurethane, or other suitable material; however, the bond strength should be tuned such that the material is retained in its position but requires approximately 1-2 N in order to remove layer.
  • blocking layer 204 may include printing or may be colored such that it provides indication to a user of the system that the blocking layer 204 should not be removed until removal of the drape is desired and deactivation of the switchable adhesive is necessary.
  • blocking layer 204 can be disposed over the entire surface area of drape cover 112. In other embodiments, blocking layer 204 may only be aligned and fitted to surface areas of drape cover 112 where the switchable adhesive portions 120 are located.
  • blocking layer 204 may be a printed/coated dye/particulate layer that is printed over the photosensitive adhesive portions 120 to prevent premature deactivation.
  • FIG. 3 shows a top view of light deactivated adhesive drape system 300 (also referred to herein as system 300 or drape system 300), which includes a drape having first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308.
  • first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308 can be disposed onto an entire tissue facing surface of drape cover 112.
  • the plurality of first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308 are dots that are pattern coated onto the tissue facing surface of drape cover 112.
  • the drape cover 112 may be an acrylic based or polyurethane based breathable film.
  • first photosensitive adhesive portions 304 include a first type of photoinitiator(s) (PI) and second photosensitive adhesive portions 308 include a second type of photoinitiator(s) different from the Pis included in the plurality of first photosensitive adhesive portions 304.
  • first photosensitive adhesive portions 304 contain a PI that is deactivated upon exposure to ultraviolet light (e.g., UVA) wavelengths and second photosensitive adhesive portions 308 contain a PI that is deactivated upon exposure to visible light wavelengths.
  • drape system 300 may also include non adhesive portions 312.
  • the PI sensitive to visible light wavelengths found in second photosensitive adhesive portions 308 will also have some sensitivity to ultraviolet light. In this manner, if UV light wavelengths are applied, the Pis of both first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308 will be deactivated. However, upon exposure to visible light wavelengths (e.g., 400 nm to 700 nm), the PI sensitive to UV light will not be significantly affected.
  • visible light wavelengths e.g. 400 nm to 700 nm
  • suitable UV light-sensitive Pi's can include Irgacure, a registered trademark of BASF SE, (such as Irgacure 651 and 2959) and suitable visible light-sensitive Pi's include H-Nu 470 & H-Nu 535, available from Spectra Group Limited Inc., and Irgacure 784 and 819.
  • first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308 are pattern coated on a transparent breathable film, such as may be made from a hydrophilic polyurethane (PU) or acrylic substance. This breathable film can include non-adhesive portions 312.
  • FIG. 4 shows a perspective view of drape system 400, which includes a drape having first photosensitive adhesive layer 404 and second photosensitive adhesive layer 408.
  • first photosensitive adhesive layer 404 includes adhesive portions 412 and perforations 416.
  • first photosensitive adhesive layer 404 can comprise a continuous coating pattern coated onto second photosensitive adhesive layer 408.
  • a hybrid construction can be used having a perforated adhesive layer (e.g., layer 404) laminated onto second photosensitive adhesive layer 408.
  • Perforations 416 enable adhesive portions of second photosensitive adhesive layer 408 to be exposed to light wavelengths that pass through the perforations 416 disposed in first photosensitive adhesive layer 404.
  • first photosensitive adhesive layer 404 and second photosensitive adhesive layer 408 can be an acrylic material.
  • first photosensitive adhesive layer 404 and second photosensitive adhesive layer 408 can be a polyurethane gel.
  • the polyurethane gel may be applied as a thicker coating than an acrylic layer and may be able to afford a higher degree of sealability for the drape against the tissue.
  • first photosensitive adhesive layer 404 and second photosensitive adhesive layer 408 can also comprise a combination of acrylic and polyurethane materials.
  • first photosensitive adhesive portions 304 and second photosensitive adhesive portions 308 can vary by application. A user can determine a suitable ratio to use based on the sensitivity of the patent tissue comprising the peri-wound area. A lower tack may be desired for patients having sensitive tissue that may be more prone to trauma upon dressing removal so more second photosensitive adhesive portions 308 may be used.
  • second photosensitive adhesive portions 308 can be deactivated even while first photosensitive adhesive portions 304 remain activated to reduce the tack to an extent allowing trauma-free drape removal.
  • the disclosed embodiments also enables two different PI adhesives to be used in a drape without risking adverse stability or incompatibility reactions between the different Pis.
  • FIG. 5 shows a top view of light deactivated adhesive drape system 500 (also referred to herein as system 500 or drape system 500), which includes a drape having first photosensitive adhesive portions 504, second photosensitive adhesive portions 508, and non-adhesive/low-adhesive portions 512.
  • first photosensitive adhesive portions 504 and second photosensitive adhesive portions 508 can be disposed in adhesive layer 116 of drape cover 112 that completely surrounds a central island of absorbent portion 108.
  • first photosensitive adhesive portions 504 comprise a first type of light sensitive adhesive and second photosensitive adhesive portions 508 comprise a second type of light sensitive adhesive.
  • first photosensitive adhesive portions 504 are sensitive to UV light while second photosensitive adhesive portions 508 are sensitive to visible light.
  • second photosensitive adhesive portions 508 are also sensitive to UV light. This enables both first photosensitive adhesive portions 504 and second photosensitive adhesive portions 508 to be deactivated upon exposure to UV light while enabling only second photosensitive adhesive portions 508 to be deactivated upon exposure to visible light.
  • each of the plurality of first photosensitive adhesive portions 504 and second photosensitive adhesive portions 508 may be pattern coated onto the tissue facing surface of drape cover 112 and drape cover 112 can be entirely covered by blocking layer 204. Upon removal of the blocking layer 204, the plurality of first photosensitive adhesive portions 504 and second photosensitive adhesive portions 508 will deactivate based upon exposure to the type of deactivating light wavelengths applied. This configuration enables a no-trauma dressing removal if the user applies UV light but still enables low-trauma dressing removal if the user applies visible light.
  • a transparent viewing area 516 may be provided to enable a user to view the wound site. As illustrated in FIG. 5, the transparent viewing area 516 may overlap or coincide with (e.g., at least partially) the non adhesive/low-adhesive portions 512 of drape system 500.
  • FIG. 6 depicts a flowchart illustrating a general process 600 for facilitating removal of a light deactivated adhesive drape system from a tissue 104 in accordance with an illustrative embodiment of the disclosure.
  • the process 600 illustrated in FIG. 6 can be implemented by a user of a reduced or negative pressure treatment system.
  • Process 600 may begin by applying a drape to a tissue 104 at step 604.
  • adhesive portions 120 can bind to the tissue 104.
  • reduced or negative pressure can be applied to the tissue 104 using a reduced or negative pressure treatment system.
  • determination is made regarding whether to remove the drape from the tissue 104.
  • process 600 may return to step 608 to make another similar determination at a later time. If determination is made to remove the drape from the tissue 104, an external stimulus is applied to the drape, including the adhesive portions 120 coupled to the drape, at step 612. In this step, step 612, a release agent 128 can be released in accordance with any of the illustrative embodiments described above to facilitate the removal of the drape from the tissue 104. At 616, the drape is removed from the tissue 104 while at least some adhesive portions of the drape are in a lower bond state, such as the bond between the adhesive portions is weakened from exposure to light.
  • FIG. 7 depicts a flowchart illustrating process 700 for facilitating removal of a light deactivated adhesive drape system from a tissue 104 in accordance with an illustrative embodiment of the disclosure.
  • process 700 may optionally include coupling a drape to a tissue at step 704.
  • the drape may have a removable blocking layer similar to layer 204 discussed above.
  • process 700 includes removing the blocking layer to expose the photosensitive adhesive layer to light.
  • Process 700 continues by applying certain deactivating light wavelengths to the photosensitive adhesive layer to deactivate the adhesive at step 712.
  • the certain deactivating light wavelengths are visible light wavelengths.
  • the drape is removed from the tissue 104 while at least some adhesive portions of the drape are in a lower bond state, such as the bond between the adhesive portions is weakened from exposure to light.

Abstract

L'invention concerne des systèmes et un procédé d'application et de retrait sans traumatisme de champs opératoires adhésifs désactivés par la lumière. Selon un aspect, un système comprend un champ opératoire, au moins une première partie adhésive photosensible ayant un premier agent antiadhérent conçue pour se désactiver lors de l'exposition à une certaine lumière ultraviolette, et au moins une seconde partie adhésive photosensible ayant un second agent antiadhérent conçue pour se désactiver lors de l'exposition à une certaine lumière visible, le système étant conçu pour être décollé d'un site tissulaire lors de l'exposition à un stimulus externe ou après cette dernière. Le système peut comprendre une couche de blocage amovible pour empêcher les secondes parties adhésives photosensibles d'être exposées prématurément à des longueurs d'onde de lumière visible de désactivation. Selon un autre aspect, l'invention concerne un procédé de retrait d'un champs opératoire par application d'une lumière visible sur le champs opératoire pour désactiver les secondes parties adhésives photosensibles et favoriser le retrait sans traumatisme du champs opératoire en l'absence de source de lumière ultraviolette.
PCT/US2019/050497 2018-09-13 2019-09-11 Systèmes et procédés de désactivation de champs opératoires adhésifs sensibles à la lumière WO2020055934A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730604P 2018-09-13 2018-09-13
US62/730,604 2018-09-13

Publications (1)

Publication Number Publication Date
WO2020055934A1 true WO2020055934A1 (fr) 2020-03-19

Family

ID=68069860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/050497 WO2020055934A1 (fr) 2018-09-13 2019-09-11 Systèmes et procédés de désactivation de champs opératoires adhésifs sensibles à la lumière

Country Status (1)

Country Link
WO (1) WO2020055934A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090277A1 (fr) * 2019-11-08 2021-05-14 Kci Licensing, Inc. Champs ayant des régions ayant des propriétés adhésives supérieures

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018136A1 (fr) * 1997-10-02 1999-04-15 Smith & Nephew Plc Adhesifs
WO2008082444A2 (fr) * 2006-10-03 2008-07-10 Arsenal Medical, Inc. Articles et procédés pour la réparation de tissus
US20090216170A1 (en) * 2008-02-27 2009-08-27 Timothy Mark Robinson System and method for healing a wound at a tissue site
WO2014202935A1 (fr) * 2013-06-17 2014-12-24 Lumina Adhesives Ab Éléments couvrants médicaux de protection cutanée, champs opératoires pour incision, barrières bactériennes pour recouvrir des plaies, dispositifs de fermeture cutanées et méthodes de traitement les utilisant
WO2017151226A1 (fr) * 2016-03-01 2017-09-08 Kci Licensing, Inc. Champ opératoire pour utilisation avec des systèmes de thérapie médicale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018136A1 (fr) * 1997-10-02 1999-04-15 Smith & Nephew Plc Adhesifs
WO2008082444A2 (fr) * 2006-10-03 2008-07-10 Arsenal Medical, Inc. Articles et procédés pour la réparation de tissus
US20090216170A1 (en) * 2008-02-27 2009-08-27 Timothy Mark Robinson System and method for healing a wound at a tissue site
WO2014202935A1 (fr) * 2013-06-17 2014-12-24 Lumina Adhesives Ab Éléments couvrants médicaux de protection cutanée, champs opératoires pour incision, barrières bactériennes pour recouvrir des plaies, dispositifs de fermeture cutanées et méthodes de traitement les utilisant
WO2017151226A1 (fr) * 2016-03-01 2017-09-08 Kci Licensing, Inc. Champ opératoire pour utilisation avec des systèmes de thérapie médicale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090277A1 (fr) * 2019-11-08 2021-05-14 Kci Licensing, Inc. Champs ayant des régions ayant des propriétés adhésives supérieures

Similar Documents

Publication Publication Date Title
US11925432B2 (en) Systems and methods for mitigating premature light deactivation of light deactivated adhesive drapes
EP3678619B1 (fr) Systèmes et méthodes pour atténuer la désactivation prématurée par la lumière de champs adhésifs désactivés par la lumière à l'aide d'une couche filtrante
CA2400228C (fr) Pansements medicaux a adhesifs multiples et leurs procedes de fabrication
US20200368075A1 (en) Systems and methods for trauma-free application and removal of light deactivated adhesive drapes
CA2939277C (fr) Systeme de traitement des plaies et methodes d'utilisation associees
RU2711863C2 (ru) Система двухкомпонентной раневой повязки
JP2015501712A (ja) 剥離可能な医療用ドレープ
RU2704601C2 (ru) Система раневой повязки
JP7374988B2 (ja) 断続閉鎖を有する皮膚閉鎖装置
AU2014274943B2 (en) Prophylactic dressing and use of same in the prevention of infection
AU2016254507A1 (en) Wound dressing
WO2020055934A1 (fr) Systèmes et procédés de désactivation de champs opératoires adhésifs sensibles à la lumière
CN111542289A (zh) 伤口敷料
WO2020018734A1 (fr) Systèmes et méthodes pour réduire ou modifier laforce de liaison de d'application et de retrait de champs adhésifs désactivés par la lumière
US20210137628A1 (en) Systems for inducing and indicating deactivation of adhesive drapes
JP2022531581A (ja) 改良型傷治療用部材
US11937893B2 (en) Systems and methods for light deactivation and removal of light deactivated adhesive drapes
KR20030062226A (ko) 신규 상처 붕대, 그의 제조 방법 및 유용한 물품
JP4660172B2 (ja) 救急用絆創膏
EP3056225A1 (fr) Système adhésif décollable
JP2011115513A (ja) 救急絆創膏
TW201642823A (zh) 可黏性治療覆蓋物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19778707

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19778707

Country of ref document: EP

Kind code of ref document: A1